High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, HCS imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of assays involving complex cellular disease models.
Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays and high content screening technologies have become more widespread.
There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of HCS assays today; the motivation to purchase assays kits versus developing homebrew; the use of specialty microplates; spending on HCS assays, reagents and consumables; and what is needed to expand the market for HCS assays. This is explored with respect to enhanced vendor offerings in HCS-engineered microplates, microchannel plates, new cell models incorporating HCS, new assay dyes and reagents, and new HCS assay kits. We conclude that HCS assay development has never been more accessible and supported by such a diversity of off-the-shelf products.
The terms High Content Imaging (HCI) and High Throughput Screening (HTS) were introduced more than a decade ago (1) and are defining the use of automated microscopy and automated image analysis in the context of drug discovery. Considered historically as two very separate disciplines with very few crossovers, this paper discusses whether you can ever do high-content imaging assays in high throughput.
The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in applying HCS coming from oncology groups. Novel reagent/probes and pathway analysis developments were considered as the tools and technology developments which will impact most on HCS over the next few years.These were the main findings of the recent market survey reviewed in this article and are used as a setting to discuss some of the latest technologies now being applied to HCS.
In the modern drug discovery industry, the development of cell based assays for High Content Screening (HCS) is necessary for the efficient screening of compound libraries. Until recently, assays for the analysis of chemotactic responses were not amenable for use in high content cell-based assay approaches. However, recent developments have enabled the investigation of chemotactic responses to be applied in cell-based High Throughput Screening (HTS) assays.
Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies.
The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount.